News about "Sanofi"

EU Approves Sanofi's Sarclisa SC as First On-Body Injector Cancer Therapy

Sanofi’s Sarclisa subcutaneous has received EU approval as the first anticancer therapy delivered via an On-Body Injector (OBI). Administered through the CirCLIQ OBI, the treatment offers flexible home or outpatient use for multiple myeloma patients while maintaining efficacy across all approved Sarclisa indications and combinations.

Sanofi | 09/06/2026 | By News Bureau

Owkin and Sanofi Partner to Develop AI Agents for Drug Discovery

Owkin and Sanofi have expanded their multi-year K Pro collaboration to develop AI agents that enhance drug discovery and development. By integrating agentic AI systems into research workflows, the partnership aims to unlock the full value of data, improve decision-making, and accelerate the development of innovative therapies.

Sanofi | 06/06/2026 | By News Bureau

FDA Grants Priority Review to Sanofi's Venglustat for Type 3 Gaucher Disease

Sanofi’s brain-penetrant investigational therapy venglustat has received FDA priority review after phase 3 data demonstrated positive efficacy and safety outcomes in patients with type 3 Gaucher disease.

Sanofi | 29/05/2026 | By News Bureau

RFiD Discovery Deploys RFID Inventory Tracking System for Sanofi R&D Sites

RFiD Discovery has implemented a passive RFID inventory management system for Sanofi, enabling real-time tracking of critical research materials at its R&D facilities in France and the United States.

Sanofi | 18/05/2026 | By News Bureau |  110

US FDA Approves Sanofi's Tzield to Delay Type 1 Diabetes Progression in Children

Sanofi’s Tzield gains US FDA approval to delay stage-III Type 1 Diabetes in children aged one year and above, the first disease-modifying therapy for stage-II T1D.

Sanofi | 24/04/2026 | By News Bureau |  101

US Food and Drug Administration Extends Review Timeline for Sarclisa Subcutaneous Formulation

FDA extends review timeline for Sanofi’s Sarclisa subcutaneous formulation, a potential first-in-class on-body injector therapy for multiple myeloma patients.

Sanofi | 23/04/2026 | By News Bureau |  154

European Commission Approves Dupixent for Young Children with Chronic Spontaneous Urticaria

The European Commission has expanded approval of Dupixent to children aged 2–11 with chronic spontaneous urticaria, offering a targeted treatment for those unresponsive to standard antihistamines.

Sanofi | 15/04/2026 | By News Bureau |  112

Sanofi's Lunsekimig Shows Promising Phase II Results in Asthma and Nasal Polyps Studies

The novel dual-targeting Nanobody met primary and key secondary endpoints in asthma and chronic rhinosinusitis trials, demonstrating improved outcomes and a favourable safety profile.

Sanofi | 08/04/2026 | By News Bureau

EU Grants Conditional Approval to Rezurock for Chronic GVHD Treatment

European Commission authorises belumosudil for patients aged 12 plus with limited treatment options, marking a significant advance in managing a life-threatening post-transplant condition.

Sanofi | 01/04/2026 | By News Bureau

Dupixent Approval in Japan Boosts Biologics Manufacturing Demand for Sanofi and Regeneron

The Ministry of Health, Labour and Welfare has granted marketing and manufacturing authorization to Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous pemphigoid (BP), a rare and debilitating skin disorder.

Sanofi | 25/03/2026 | By Darshana |  148